NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - Equities researchers at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of NeoGenomics in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.02). The consensus estimate for NeoGenomics' current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for NeoGenomics' Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.10) EPS and FY2026 earnings at $0.07 EPS.
NEO has been the subject of a number of other reports. Bank of America lifted their price objective on NeoGenomics from $18.00 to $19.00 and gave the stock a "neutral" rating in a research note on Friday, December 13th. Needham & Company LLC restated a "buy" rating and issued a $19.00 price target on shares of NeoGenomics in a report on Friday, January 10th. Jefferies Financial Group began coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price target on the stock. Finally, Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, NeoGenomics currently has a consensus rating of "Moderate Buy" and an average target price of $20.30.
Check Out Our Latest Stock Report on NeoGenomics
NeoGenomics Trading Up 1.1 %
Shares of NASDAQ NEO traded up $0.16 during midday trading on Thursday, hitting $14.66. The stock had a trading volume of 623,580 shares, compared to its average volume of 1,353,434. The company's 50-day simple moving average is $16.56 and its 200 day simple moving average is $15.68. The firm has a market cap of $1.88 billion, a P/E ratio of -24.03 and a beta of 1.24. NeoGenomics has a fifty-two week low of $12.13 and a fifty-two week high of $19.11. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. During the same quarter in the previous year, the company posted ($0.06) EPS. The business's revenue for the quarter was up 10.5% compared to the same quarter last year.
Insider Activity
In related news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now owns 37,129 shares of the company's stock, valued at $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is owned by company insiders.
Institutional Investors Weigh In On NeoGenomics
Several institutional investors and hedge funds have recently added to or reduced their stakes in NEO. Versant Capital Management Inc raised its position in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after purchasing an additional 1,142 shares during the last quarter. Quarry LP bought a new position in NeoGenomics during the 3rd quarter worth $40,000. Blue Trust Inc. raised its position in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock worth $46,000 after purchasing an additional 987 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in NeoGenomics during the 2nd quarter worth $57,000. Finally, KBC Group NV raised its position in NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock worth $67,000 after purchasing an additional 1,127 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
